Skip to main content
Back
Watch Compare

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Data quality: 83%
RVPH
NASDAQ Manufacturing Chemicals
$0.77
▼ $0.08 (-8.88%)
Mkt Cap: 10.92 M
Price
$0.85
Mkt Cap
10.92 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -24.59 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-971.25%
Below sector avg (-54.47%)
ROIC-748.32%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
0.00
Below sector avg (0.30)
Current Ratio1.39
Interest Coverage-1507.24

Valuation

PE (TTM|NTM)
-0.55 | -0.93
Above sector avg (-1.49)
P/B Ratio2.40
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -0.6 -1.5
P/B 2.4 1.6
ROE % -971.3 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E 0.0 0.3

Analyst Price Target

5 analysts
Buy
Current
$0.77
+7458.4%
Target
$58.20
$1.00
$40.00
$140.00
Forecast
Forward P/E -0.93
Forward EPS -$0.83
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.83
-$1.20 – -$0.46
 0.0 4
FY2026 -$2.48
-$4.64 – -$0.95
 0.0 5

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$1.07 -$5.19 -386.6%
Q32025 -$1.94 -$1.20 +38.2%
Q22025 -$2.20 -$2.40 -9.1%
Q12025 -$3.65 -$2.60 +28.8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -19.86 M
ROE -971.25% ROA -153.00%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -24.59 M
ROIC -748.32% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 1.39
Interest Coverage -1507.24 Asset Turnover N/A
Working Capital 3.77 M Tangible Book Value 4.55 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.55 Forward P/E -0.93
P/B Ratio 2.40 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -225.18%
Market Cap 10.92 M Enterprise Value -2.26 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -1.92 OCF / Share -1.92
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 123.81%
SBC-Adj. FCF -26.72 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -19.86 M -29.92 M -39.26 M -24.34 M -8.52 M
EPS (Diluted) — — — — —
Gross Profit — — — — —
Operating Income -20.20 M -30.80 M -39.50 M -24.31 M -10.10 M
EBITDA — — — — —
R&D Expenses 11.71 M 22.91 M 31.42 M 18.95 M 4.85 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 13,402.0 18,497.0 — — 0.0
Income Tax 18,889.0 19,514.0 16,949.0 20,777.0 8,281.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15.92 M 15.50 M 23.70 M 18.92 M 31.40 M
Total Liabilities 7.28 M 14.69 M 17.98 M 6.61 M 2.72 M
Shareholders' Equity 8.65 M 812,572.0 5.72 M 12.32 M 28.69 M
Total Debt 406,875.0 458,154.0 — — —
Cash & Equivalents 14.44 M 13.48 M 23.37 M 18.52 M 29.69 M
Current Assets 15.10 M 14.68 M — — —
Current Liabilities 7.28 M 14.60 M 17.18 M 6.04 M 2.34 M